Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

137.41 -0.47 (-0.34%)
Streaming Delayed Price Updated: 9:54 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
News headline image
The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500
As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the... 
Via PredictStreet
Topics Economy Intellectual Property Stocks
News headline image
The $3 Billion Bet: How Isomorphic Labs is Rewriting the Rules of Drug Discovery with Eli Lilly and Novartis
In a move that has fundamentally reshaped the landscape of the pharmaceutical industry, Isomorphic Labs—the London-based drug discovery arm of Alphabet Inc. (NASDAQ: GOOGL)—has solidified its position... 
Via TokenRing AI
Topics Artificial Intelligence
Novartis AG (NYSE:NVS) Stands Out as a Dependable Dividend Stock with Strong Fundamentals ↗
Via Chartmill
News headline image
The Great Unlocking: How AlphaFold 3’s Open-Source Pivot Sparked a New Era of Drug Discovery
The landscape of biological science underwent a seismic shift in November 2024, when Google DeepMind, a subsidiary of Alphabet Inc. (NASDAQ: GOOGL), officially released the source code and model... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Decoding Life’s Blueprint: How AlphaFold 3 is Redefining the Frontier of Medicine
The year 2025 has cemented a historic shift in the biological sciences, marking the end of the "guess-and-test" era of drug discovery. At the heart of this revolution is AlphaFold 3, the latest AI... 
Via TokenRing AI
Topics Artificial Intelligence Bonds
News headline image
Invest Outside the U.S. With These Top International ETFs ↗
Compare how fund size, holdings, and portfolio breadth set VEA and SPDW ETFs apart for diversified investors. 
Via The Motley Fool
Topics ETFs
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Pfizer Leads New Wave Of 2026 US Drug Price Hikes Despite Trump’s Drug Cost Crackdown: Report ↗
Drugmakers are outlining 2026 list price changes, with most adjustments typically announced in January. 
Via Stocktwits
Topics Economy Government
News headline image
The “Operating System of Life”: How AlphaFold 3 Redefined Biology and the Drug Discovery Frontier
As of late 2025, the landscape of biological research has undergone a transformation comparable to the digital revolution of the late 20th century. At the center of this shift is AlphaFold 3, the... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
AlphaFold’s Five-Year Reign: 3 Million Researchers and the Dawn of a New Biological Era
In a milestone that cements artificial intelligence as the most potent tool in modern science, Google DeepMind’s AlphaFold has officially surpassed 3 million users worldwide. This achievement coincides... 
Via TokenRing AI
Topics Artificial Intelligence Climate Change
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme... 
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Value Investment Case ↗
Novartis (NVS) presents a classic value investing case: a financially strong pharmaceutical leader trading at a discount to peers, with high profitability and a solid dividend. 
Via Chartmill
News headline image
The Biological Turing Point: How AlphaFold 3 and the Nobel Prize Redefined the Future of Medicine
In the final weeks of 2025, the scientific community is reflecting on a year where the boundary between computer science and biology effectively vanished. The catalyst for this transformation was... 
Via TokenRing AI
Topics Artificial Intelligence Initial Public Offering
News headline image
Stock Market Today, Dec. 23: Novo Nordisk Surges After FDA Approves Oral Wegovy Weight Loss Pill ↗
On Dec. 23, 2025, investors weighed a newly approved oral obesity pill’s first-mover edge and its ripple effects across healthcare. 
Via The Motley Fool
Topics Stocks
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
2 Top Stocks to Buy and Hold for the Long Term ↗
Both have crushed the market this year. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗
The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief. 
Via Stocktwits
Topics Government World Trade
News headline image
Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump ↗
Dow Jones stock Merck forged a Most Favored Nation agreement with the Trump administration on Friday. 
Via Investor's Business Daily
Topics Government Stocks
News headline image
AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗
This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program. 
Via Stocktwits
Topics Economy Government
News headline image
White House Readies Drug Price Deals With AbbVie, Novartis, Roche ↗
AbbVie and other drugmakers may announce U.S. drug pricing deals on Friday as the White House pushes lower prices and Medicare payment reforms. 
Via Benzinga
News headline image
Salesforce Stock Rises On BTIG Buy Rating And Novartis Agentforce Deal ↗
Salesforce Inc (NYSE:CRM) shares moved higher Wednesday after BTIG kicked off coverage with a Buy rating and a $335 price target, while the company scored a major win with Novartis choosing its... 
Via Benzinga
News headline image
Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗
The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing. 
Via Stocktwits
Topics Government World Trade
News headline image
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Financials ↗
Novartis (NVS) offers a reliable 3.27% dividend yield, backed by strong profitability, a healthy balance sheet, and a history of consistent payouts. 
Via Chartmill
News headline image
Novartis&#39; Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder ↗
Novartis reports Phase 3 results showing that combining ianalumab with eltrombopag significantly extends disease control and improves sustained platelet response in ITP patients. 
Via Benzinga
News headline image
Silver Shines as Global Tariff Storm Gathers: A Safe-Haven and Strategic Imperative in 2025
As global trade tensions escalate dramatically throughout late 2024 and 2025, marked by a surge in protectionist policies and tit-for-tat tariffs, silver has emerged as a dual-threat asset: a critical... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Can the Vanguard International High Dividend Yield Index Fund ETF Shares Outperform Again in 2026? ↗
This low-cost international dividend ETF nearly doubled the S&P 500's return in 2025 -- but replicating that performance will require the stars to align once more. 
Via The Motley Fool
Topics ETFs Economy Stocks
News headline image
Is Alnylam Pharmaceuticals a Millionaire Maker? ↗
This hot biotech stock could have a lot more room to run. 
Via The Motley Fool
News headline image
Global Prescription Drug Market Poised for Trillion-Dollar Surge by 2035
The global prescription drugs market is on the cusp of a significant expansion, with recent market reviews and forecasts projecting a robust growth trajectory through 2035. This anticipated surge,... 
Via MarketMinute
Topics Artificial Intelligence Death Intellectual Property
News headline image
Morgan Stanley Downgrades Regeneron (REGN) to Equal-Weight, Citing Fair Valuation and Pipeline Scrutiny
New York, NY – December 3, 2025 – In a significant move reverberating through the biotechnology sector, investment banking giant Morgan Stanley has downgraded Regeneron Pharmaceuticals (NASDAQ: REGN)... 
Via MarketMinute
Topics Intellectual Property
News headline image
Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound ↗
Janux shares plunged after the JANX007 trial update prompted widespread target cuts, even as retail traders framed the selloff as poised for a rebound. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.